The global emergency contraceptives market is expected to grow at an unprecedented CAGR due to increase in the global female population. Increase in the public awareness in making right decisions about their sensual and reproductive health, technological advancements and an increase in the development of effective female contraceptive medicine and devices, and availability of products in the market might fuel the emergency contraceptives market. Furthermore, low cost of the products, rise in the adoption of modern emergency contraceptives in developing countries, ease of administration of emergency contraceptive pills, and high effectiveness and convenience in emergency contraceptive devices might boost the global emergency contraceptives market. However, adverse effects like nausea, headache associated with the emergency contraceptive pills, lack of skilled professionals for the insertion of intrauterine devices, and product failures in some cases might hamper the emergency contraceptives market.A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-emergency-contraceptives-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
Emergency contraceptives market segmented on the basis of product type, and distribution channel
Based on product type, emergency contraceptives market has been segmented into the following:
Pills
Combined oestrogen and progestin pills
Progestin-only (as Levonorgestrel) pills
Antiprogestin (as mifepristone) pills
Eulipristal acetate pills
Based on the distribution channel, emergency contraceptives market has been segmented into the following:
Hospital pharmacies
Retail pharmacies
Online pharmacies
Others
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-emergency-contraceptives-market/#ulp-c654SbFYO64MsOhu[/URL]
Market players betting heavily by investing in manufacturing of emergency contraceptives to increase their share in the emergency contraceptives market. Launching of new products, collaborations, acquisitions and mergers, approvals as over the counter (OTC) product from various drug regulators such as U.S. Food and Drug Administration, and research and developments are some key strategies followed by various pharmaceutical companies to increase the share in the global emergency contraceptives market. For instance, in August 2010, U.S. Food and Drug Administration approved the Ella (Eulipristal acetate pills) as emergency contraceptive pills which are developed by HRA pharmaceuticals. Similarly, In February 2011, Teva Pharmaceuticals received an approval from the FDA for requesting non-prescription status for Plan B One Step for women under the age of 17.
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-emergency-contraceptives-market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the players in the emergency contraceptives market are Gynetics NV (Belgium), Teva Pharmaceutical Industries Ltd. (Israel), Uniprix group (Canada), Gavis Pharmaceuticals LLC, (A Lupin Group Company) (U.S.), HRA Pharma (Paris), and Mankind Pharma (India) to name a few.